AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises. See why AZN stock is a Buy.

A £4.8million investment in a Cambridge x Manchester Innovation Partnership has been announced by the government. The funding ...

Danaher Corporation DHR recently partnered with AstraZeneca PLC AZN to develop and market novel diagnostic tools aimed at ...

Cambridge and Manchester have forged a pioneering collaboration to harness the combined strengths of their respective ...

Construction of AstraZeneca’s new global and R&D headquarters in Cambridge should have been completed last autumn – but builders are struggling to meet a revised deadline of May 2019.

Sortera Bio, a Cambridge biotech based on IP developed at the MRC Laboratory of Molecular Biology, has attracted big hitting ...

Additionally, we have even greater US investment in manufacturing and R&D planned, leveraging our two large R&D sites in Gaithersburg MD and Cambridge MA. Overall, we are making excellent progress ...

AstraZeneca PLC has agreed to pay $51 million to settle claims it entered into an unlawful deal to limit competition for ...

CAMBRIDGE, Britain (AP) — CAMBRIDGE, Britain (AP) — Astrazeneca PLC (AZN) on Tuesday reported first-quarter profit of $2.92 billion. On a per-share basis, the Cambridge, Britain-based company ...

The pharmaceutical company AstraZeneca has filed a federal lawsuit against Utah Attorney General Derek Brown and Utah ...